Last reviewed · How we verify
Sodium Polystyrene Sulfonate Oral Suspension [SPS] — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Sodium Polystyrene Sulfonate Oral Suspension [SPS] (Sodium Polystyrene Sulfonate Oral Suspension [SPS]) — University of California, Irvine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sodium Polystyrene Sulfonate Oral Suspension [SPS] TARGET | Sodium Polystyrene Sulfonate Oral Suspension [SPS] | University of California, Irvine | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sodium Polystyrene Sulfonate Oral Suspension [SPS] CI watch — RSS
- Sodium Polystyrene Sulfonate Oral Suspension [SPS] CI watch — Atom
- Sodium Polystyrene Sulfonate Oral Suspension [SPS] CI watch — JSON
- Sodium Polystyrene Sulfonate Oral Suspension [SPS] alone — RSS
Cite this brief
Drug Landscape (2026). Sodium Polystyrene Sulfonate Oral Suspension [SPS] — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-polystyrene-sulfonate-oral-suspension-sps. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab